Document Detail

Stereotactic body radiotherapy for oligometastases.
MedLine Citation:
PMID:  23276369     Owner:  NLM     Status:  MEDLINE    
The management of metastatic solid tumours has historically focused on systemic treatment given with palliative intent. However, radical surgical treatment of oligometastases is now common practice in some settings. The development of stereotactic body radiotherapy (SBRT), building on improvements in delivery achieved by intensity-modulated and image-guided radiotherapy, now allows delivery of ablative doses of radiation to extracranial sites. Many non-randomised studies have shown that SBRT for oligometastases is safe and effective, with local control rates of about 80%. Importantly, these studies also suggest that the natural history of the disease is changing, with 2-5 year progression-free survival of about 20%. Although complete cure might be possible in a few patients with oligometastases, the aim of SBRT in this setting is to achieve local control and delay progression, and thereby also postpone the need for further treatment. We review published work showing that SBRT offers durable local control and the potential for progression-free survival in non-liver, non-lung oligometastatic disease at a range of sites. However, to test whether SBRT really does improve progression-free survival, randomised trials will be essential.
Alison C Tree; Vincent S Khoo; Rosalind A Eeles; Merina Ahmed; David P Dearnaley; Maria A Hawkins; Robert A Huddart; Christopher M Nutting; Peter J Ostler; Nicholas J van As
Related Documents :
17116819 - Vocal outcomes after laser resection of early-stage glottic cancer with adjuvant cryoth...
24266949 - Number of lymph nodes associated with maximal reduction of long-term mortality risk in ...
24971429 - Gemicitabine-induced radiation recall phenomenon in 2 distinctive sites on the same pat...
1127199 - Communication for the aphasic stroke patient: assessment and therapy.
24484269 - Ebus-tbna for non-small cell lung cancer staging.
23948859 - Volume-based assessment by (18)f-fdg pet/ct predicts survival in patients with stage ii...
21441299 - Bevacizumab treatment to progression after chemotherapy: outcomes from a u.s. community...
23239699 - Can radiobiological parameters derived from squamous cell carcinoma of the head and nec...
16015529 - A case against surgery for most iiia non-small cell lung cancer.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  The Lancet. Oncology     Volume:  14     ISSN:  1474-5488     ISO Abbreviation:  Lancet Oncol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-01     Completed Date:  2013-04-03     Revised Date:  2014-08-18    
Medline Journal Info:
Nlm Unique ID:  100957246     Medline TA:  Lancet Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  e28-37     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Disease-Free Survival
Dose Fractionation
Liver Neoplasms* / radiotherapy,  secondary
Lung Neoplasms* / radiotherapy,  secondary
Neoplasm Metastasis* / pathology,  radiotherapy
Radiosurgery / methods*
Radiotherapy, Image-Guided
Grant Support
C46/A2131//Cancer Research UK

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Molecular diagnostics in paediatric glial tumours.
Next Document:  The price of autonomy: should we offer individuals a choice of colorectal cancer screening strategie...